136 related articles for article (PubMed ID: 23038966)
1. [Complex karyotype is a marker of very poor prognosis in over 70-year-old patients with acute myeloid leukemia and extended types of myelodysplastic syndrome and high comorbidity index].
Gritsaev SV; Martynkevich IS; Abdulkadyrov KM; Ivanova MP; Petrova EV; Zapreeva IM; Tiranova SA; Potikhonova NA
Ter Arkh; 2012; 84(7):16-21. PubMed ID: 23038966
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for therapy-related acute myeloid leukaemia (t-AML)--a single centre experience.
Suvajdžić N; Cvetković Z; Dorđević V; Kraguljac-Kurtović N; Stanisavljević D; Bogdanović A; Djunić I; Colović N; Vidović A; Elezović I; Tomin D
Biomed Pharmacother; 2012 Jun; 66(4):285-92. PubMed ID: 22401928
[TBL] [Abstract][Full Text] [Related]
3. [Study on the transformation from myelodysplastic syndromes into acute leukemias].
Shi J; Shao Z; Liu H; Li K; Song L; Zhang Y; Zheng Y; Chen G; Chu Y; He H; Zhao M; He G; Feng B; Hao Y; Yang T; Yang C
Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):351-4. PubMed ID: 11877096
[TBL] [Abstract][Full Text] [Related]
4. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.
Knipp S; Hildebrand B; Kündgen A; Giagounidis A; Kobbe G; Haas R; Aul C; Gattermann N; Germing U
Cancer; 2007 Jul; 110(2):345-52. PubMed ID: 17559141
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
6. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
Balleisen S; Kuendgen A; Hildebrandt B; Haas R; Germing U
Leuk Res; 2009 Sep; 33(9):1189-93. PubMed ID: 19428106
[TBL] [Abstract][Full Text] [Related]
8. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Kantarjian H; Beran M; Cortes J; O'Brien S; Giles F; Pierce S; Shan J; Plunkett W; Keating M; Estey E
Cancer; 2006 Mar; 106(5):1099-109. PubMed ID: 16435387
[TBL] [Abstract][Full Text] [Related]
12. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
13. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
14. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
Giles F; Rizzieri D; Karp J; Vey N; Ravandi F; Faderl S; Khan KD; Verhoef G; Wijermans P; Advani A; Roboz G; Kantarjian H; Bilgrami SF; Ferrant A; Daenen SM; Karsten V; Cahill A; Albitar M; Mufti G; O'Brien S
J Clin Oncol; 2007 Jan; 25(1):25-31. PubMed ID: 17146105
[TBL] [Abstract][Full Text] [Related]
15. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
[TBL] [Abstract][Full Text] [Related]
16. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
Rizzieri DA; O'Brien JA; Broadwater G; Decastro CM; Dev P; Diehl L; Beaven A; Lagoo A; Gockerman JP; Chao NJ; Moore JO
Cancer; 2009 Jul; 115(13):2922-9. PubMed ID: 19452542
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia and myelodysplastic syndromes in older patients.
Estey E
J Clin Oncol; 2007 May; 25(14):1908-15. PubMed ID: 17488990
[TBL] [Abstract][Full Text] [Related]
19. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
Bolaños-Meade J; Guo C; Gojo I; Karp JE
Leuk Res; 2004 Jun; 28(6):571-7. PubMed ID: 15120933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
